SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ergobilt (ERGB) - Ergonomic Chairs -- Ignore unavailable to you. Want to Upgrade?

To: Mark Rutheiser who wrote (714)2/27/1998 10:31:00 AM
From: Jim Patterson  Respond to of 900
 
If you read and believed and understand the Revenue recognition change they are making, It is a wonder that they made $$ at all.
In about 4-5 weeks we should have Q4 numbers. They should be very strong after the change.

I like the Big volume, but Technicaly the stock really needs $ 6 to get out of the woods.

Jim



To: Mark Rutheiser who wrote (714)2/28/1998 1:35:00 AM
From: Scott D. Hakala  Respond to of 900
 
Mark, ERGB took a bunch of charges and development expenses. Look at the sales and gross margins. They are still way up and solid. The operating expenses are high. I understand that this was due to a lot of development activities and some initial charges associated with the CTSS deal. If my sources are correct, the Company will be up in the next quarter and should still produce solid earnings in the next year.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News